Fra Redeye
Pledpharma: CMD takeaways
Mar 27 2019
Yesterday’s CMD provided a thorough update of the ongoing activities with PledOx and Aladote.
Our key takeaways: 1) The new POP study results support further development of Aladote, 2) Recruitment to the POLAR trials seem to be on track (no new guidance provided), 3) Preclinical studies will be carried out during 2019 to explore the opportunity of PledOx in taxanes, and 4) Up-listing to the Nasdaq Main Market, expected to happen in Q4 2019.
All in all, we feel a growing conviction of Pledpharma, as a late-stage clinical development play, and we reiterate our base case fair value of SEK 52.